Agenda: Day 1

All session times are in Eastern Time (ET)

There are no agenda items with this track

9:00 am

9:00 am

NETWORKING

Enter Networking Lounge, Connect with your Industry Colleagues

  • Start your day off right and make connections with industry leadership.
  • Join “drop-in” roundtables discussing current and relevant topics.
  • Schedule 1-2-1 video meetings with peers or vendors.
  • Gather essential content and get exclusive offers at virtual exhibit booths.

10:00 am

10:00 am

Welcome from your Host

Gain insight into today’s sessions so you can get the most out of your experience and maximize your value.

10:10 am

10:10 am

Opening Keynote: CANADIAN HEALTHCARE LANDSCAPE

Position your Company to Succeed in the Brave New World of Canadian Healthcare

Canadians were severely impacted during COVID-19 due to a lack of domestic pharmaceutical R&D and manufacturing. Is now the time for a reset to the industry/government partnership? Set your company up for future success with insights from an experienced and objective voice, André Picard. Engage in a high-level conversation on:

  • The history of the pharma industry in Canada
  • Valuable lessons to actionable learnings from the pandemic
  • Indications that ‘the times, they are a changing’

 

Carve out your company’s place in the evolving world of Canadian healthcare.

11:00 am

11:00 am

Panel Discussion: VIEW FROM THE TRENCHES

Overcome Risk and Seize Opportunities with Insight from Canada’s Key Health System Players

With PMPRB updates on hold again, and recent tweaks to the CADTH compliance process, a pandemic-shaken health system, and emerging opportunities in rare diseases, there is a lot of work to be done. Dialogue with government, regulatory, industry and patient group leaders as they consider the industry outlook and determine the immediate and future impact on your business. Take away high-level perspectives on:

  • Emerging opportunities within Canada’s impending national strategy for high-cost drugs for rare diseases
  • Incorporating best practices and lessons learned during the COVID-19 pandemic
  • Overcoming early stumbling blocks with the updated PMPRB regulations

Prepare your organization for opportunity and risk in the ‘new normal’

11:30 am

11:30 am

FIRESIDE CHAT: CADTH UPDATE

Learning from the COVID-19 Pandemic – How can it Guide Navigation in the Future for a Successful Submission the First Time Around

Accurately interpreting the impact of these  learnings is fundamental to your company’s bottom line. Source intelligence to:

  • Gain a comprehensive understanding of the information requirements for drug submissions to CADTH.
  • Adopt best practices to better manage your product submissions under the revised process.
  • Navigate the changes seamlessly and efficiently.

Position your product for a successful submission through the updated CADTH review process.

12:00 pm

12:00 pm

Industry Expert: IQVIA

Practical Applications for RWE to Demonstrate Evidence and Support Access in the Next Normal

Healthcare is undergoing profound changes that are impacting on both the drug development process and access to medications. Learn how the COVID-19 pandemic has altered the healthcare landscape in the short term and the potential downstream effects that may manifest over the longer term. Add to this seismic event the policy changes on the horizon,  increased demand for credible and objective evidence, and growing pressure from payers, pharmaceutical companies must stay abreast of changing realities when developing strategies and bringing products to market.
  • Examine which therapeutic areas have been most affected by the pandemic and the longer-term implications for healthcare
  • Understand how COVID-19 had impacted the timeline for access to new medications and pan-Canadian negotiations for optimal pricing
  • Learn how access to leading data resources can provide you with powerful insights that will enable you to accelerate the clinical to commercial journey

12:30 pm

12:30 pm

Panel Discussion: RARE DISEASE MARKET OUTLOOK

Paving the Way Forward for Rare Disease Therapies with Lessons Learned from COVID-19

Health Canada is preparing to implement a national strategy to help fund high-cost drugs for rare diseases by 2022–2023. How can you best prepare, and what can we learn from the COVID-19 vaccine journey? Inform your market access strategy with the experience of these market leaders. Establish your game plan by:

  • Determining the types of partnerships and funding that will be key to the successful development of drugs for rare diseases
  • Analyzing the impact of recently increased government funding on the overall treatment pipeline
  • Visualizing potential safe and expeditious routes to commercialization for these medicines

Chart a course to succeed in the new market access model for rare disease therapies

1:00 pm

1:00 pm

NETWORKING

Build Relationships and Visit Virtual Booths

Expand your network and exchange expertise with your peers. Take advantage of our intuitive platform to deepen your knowledge and connect with industry leaders and experts.

  • Pose your biggest questions to leading solution providers through 1:1 video conversations or chat.
  • Join “drop-in” roundtables in the networking lounge and make connections that last beyond these two days.
  • Experience live demos and test drive new technology. Source leading-edge content from virtual booths.

1:30 pm

1:30 pm

Afternoon Keynote: INTERNATIONAL REFERENCE PRICING (IRP)

An Overview and Outlook for IRP in North America

IRP is a frequently tossed-around term used in reference to controlling rising drug prices in both Canada and the US. Leverage an in-depth understanding of the history and future consequences for your brands/products. Gain critical insights including:

  • Incorporating IRP, the absence of price transparency and role of confidential agreements & patient access schemes
  • Informing yourself via a case study how the new basket of 11 reference countries is intended to lower Canadian drug prices to OECD median
  • Evaluating the proposed US IRP regulatory proposals and their potential for implementation in current political environment

Assess the impact of IRP on your upcoming launch sequencing & patient access

2:15 pm

2:15 pm

Panel Discussion: THE ROAD TO ADVANCED THERAPEUTICS

Assessing the State of Play: Are Gene Therapies the Next Big Game Changers?

Although still considered by some an experimental technique, gene therapy, which focuses on the genetic modification of cells, is poised to become much more prevalent. Researchers are constantly unveiling new approaches to gene therapy. Inform your development pipeline with an in-depth understanding of these strategies, including:

  • Replacing a mutated disease-causing gene with a healthy copy of the gene
  • Inactivating, or “knocking out,” a mutated gene that is functioning improperly
  • Introducing a new gene into the body to help fight a disease

Equip your team with actionable insights in your development of efficacious gene therapy products

3:00 pm

3:00 pm

Industry Expert: REAL-WORLD EVIDENCE

Understand How Real-World Evidence Is Impacting Drug Development And Approval

As seen with the expedited approval of the COVID-19 vaccines, governments, industry players and other stakeholders are increasingly being required to incorporate quality data to support their submissions for reimbursement. Explore new approaches using Real World Evidence (RWE) to improve the value proposition of your medicines. Take away actionable insights to:

  • Enhance the efficacy of your medications on individual patient outcomes
  • Evaluate the impact of RWE on overall patient population health in those taking your medication
  • Partner with stakeholders to access data pertinent to reimbursement

Prove and improve the value, efficacy and impact of your medications with RWE

3:30 pm

3:30 pm

Panel Discussion: PRIVATE PAYERS’ PERSPECTIVE

Ensure A Pathway to Access & Reimbursement Among Private Payors

Continued tightening of access to private payor formularies combined with a move to outsource benefit plans and administration to third parties for some payors, means more barriers to access in this market than before. Hone your private payor access strategy by understanding new market developments and payer priorities. Create an action plan to:

  • Leverage elements of successful public PLA submissions and adapt them for the private payer market
  • Analyze the influence of public payor decisions on private payors to increase your preparedness
  • Discover what pharma companies can do to optimize the ROI of their submissions to private payors

Gain insight into what private payors need and succeed with a tailored approach to securing a PLA

4:15 pm

4:15 pm

Summary from your Host

Review the key solutions and takeaways from today’s sessions. Source a summary of actions points to implement in your work. Discuss tomorrow’s highlights!

4:20 pm

4:20 pm

Virtual Happy Hour

  • Get to know fellow delegates in “drop-in” virtual roundtables.
  • Engage in 1:1 video conversation with peers or vendors.
  • Connect with other attendees based on similar interests and business objectives using our “recommend matches” tool.

4:45 pm

4:45 pm

Conference Day 1 Adjourns

Get the latest news

*Privacy Policy